CFD's zijn complexe instrumenten en gaan gepaard met een hoog risico snel kapitaal te verliezen als gevolg van hefboommechanismen. 74.2% an de retailbeleggers lijdt verlies op de handel in CFD's met deze aanbieder. U dient zorgvuldig te overwegen of u begrijpt hoe CFD's werken en of u het zich kunt veroorloven om hoge risico's te nemen op het verliezen van uw kapitaal.

Close

Handelen Eli Lilly LLY

EliLilly live grafieken

instrument_fundamentals

Weekly Search
Weekly
Daily
Datum Sluit Verandering % verandering Openen Piek Bodem

Laatste marktnieuws

Tommy Yap 2025 Mar 22, 16:00

Week Ahead: Investor Eyes on U.S. Inflation & Core PCE for Fed’s Next Move

Forex Indices
Frances Wang 2025 Mar 20, 16:00

Stock indices news: US stock indices rose on Fed decision

Indices
Tommy Yap 2025 Mar 20, 16:00

Morning Note: Oil Sanctions, Canada Data, Ripple's Space Gamble

Morning Note Oil Forex
Frances Wang 2025 Mar 19, 16:00

US stock indices update: NASDAQ 100, Dow Jones 30 and S&P 500 Forecast

Indices
Tommy Yap 2025 Mar 19, 16:00

Morning Note: SNB Rate Cut Expected, BoE Decision & Accenture Earnings in Focus

Morning Note Forex
Frances Wang 2025 Mar 18, 16:00

Stock market today: NASDAQ Index, SP500, Dow Jones Forecasts

Stocks
Tommy Yap 2025 Mar 18, 16:00

Morning Note: BoJ Holds Rates, Fed Decision Looms & Tencent Earnings in Focus

Morning Note BoJ Fed
Frances Wang 2025 Mar 17, 16:00

Stock market today: Dow, S&P 500, Nasdaq remain steady on tariff tension

Stocks Indices

Info

Spread

5.51

Spread (%)

0.6587 %

Hefboom

1:5

Dagrente kopen

-0.0597 %

Dagrente verkopen

-0.0292 %

Valuta

USD

Openingstijden

Markt gesloten

Maandag

13:31 - 19:59

Dinsdag

13:31-19:59

Woensdag

13:31-19:59

Donderdag

13:31-19:59

Vrijdag

13:31-19:59

instr__analysis_statistics

Openen

---

Vorige Sluiten

---

52-weekse hoog/laag

--- – ---

Beurswaarde

752280207360

Uitstaande aandelen

898169984

Datum winstcijfer (volgende)

1997-10-16

Div. rend.

2025-03-10

Ex-dividenddatum

2025-02-14

Jaarlijks verwachte dividendpercentage

6

Jaarlijks verwachte dividendrendement

0.0072

Winst per aandeel

11.73

Meer informatie over dit instrument

Eli Lilly Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Gerelateerde instrumenten

Activa
Verkoop
Koop
% verandering
Gerelateerde instrumenten
Trustpilot